Gedeon Richter PLC (RGEDF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gedeon Richter PLC (RGEDF) trades at $41.81 with AI Score 53/100 (Grade B). Gedeon Richter PLC is a Hungarian pharmaceutical company specializing in the development and manufacture of pharmaceuticals. Market cap: $7.65B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for RGEDF: RGEDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGEDF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
RGEDF: 2/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Gedeon Richter PLC (RGEDF) Healthcare & Pipeline Overview
Gedeon Richter PLC, a leading Hungarian pharmaceutical company, excels in the development and manufacturing of innovative pharmaceuticals, leveraging a robust distribution network and a commitment to research and development to enhance healthcare solutions globally.
What Is the Investment Thesis for RGEDF?
Gedeon Richter PLC presents a compelling investment thesis driven by its robust financial metrics, including a market cap of $7.65B and a profit margin of 24.8%. The company is poised for growth through its strong pharmaceutical pipeline and strategic expansion into emerging markets. With a P/E ratio of 9.3, it offers a valuation that is attractive compared to industry peers. The company’s commitment to R&D, reflected in its significant gross margin of 67.5%, positions it well to capitalize on new therapeutic areas. Additionally, the ongoing demand for pharmaceuticals globally, coupled with an aging population, serves as a catalyst for sustained revenue growth. However, potential risks include regulatory challenges and competition in the pharmaceutical sector, which investors may want to evaluate.
Based on FMP financials and quantitative analysis
RGEDF Key Highlights
Market Cap of $7.65B reflects strong market position in pharmaceuticals.
- Profit Margin of 24.8% indicates efficient operations and profitability.
- Gross Margin of 67.5% exceeds industry averages, showcasing effective cost management.
- P/E Ratio of 9.3 suggests attractive valuation compared to peers.
- Dividend Yield of 4.67% provides a steady income stream for investors.
Who Are RGEDF's Competitors?
RGEDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| RHHBY Roche Holding AG | $58.24 | +4.90% | $371B | 61 |
| NVS Novartis AG | $160.31 | +3.73% | $305B | 57 |
| SNY Sanofi | $45.44 | -0.85% | $109B | 58 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| PFE Pfizer Inc. | $28.24 | +3.63% | $161B | 67 |
| ALBBY Alibaba Health Information Technology Limited | $8.88 | +0.00% | $8.00B | 46 |
| ALBHF Alibaba Health Information Technology Limited | $0.44 | +0.00% | $7.12B | 45 |
| RADLY Raia Drogasil S.A. | $3.39 | +4.31% | $5.93B | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGEDF's Key Strengths?
Strong financial performance with high profit and gross margins.
- Established reputation and brand in the pharmaceutical market.
- Diverse product portfolio across multiple therapeutic areas.
- Robust R&D capabilities for innovative drug development.
What Are RGEDF's Weaknesses?
Dependency on specific therapeutic areas for revenue.
- Potential challenges in regulatory approvals for new drugs.
- Limited geographic presence compared to larger global competitors.
- Vulnerability to pricing pressures in the pharmaceutical industry.
What Could Drive RGEDF Stock Higher?
Introduction of new pharmaceutical products in emerging markets.
- Continuous investment in R&D for innovative therapies.
- Expansion of distribution networks to enhance market reach.
- Strategic partnerships to enhance product offerings and market access.
- Commitment to sustainability and green chemistry practices.
What Are the Key Risks for RGEDF?
Regulatory challenges impacting drug approvals.
- Intense competition from established pharmaceutical companies.
- Market volatility affecting pricing and profitability.
- Risks associated with patent expirations and generic competition.
What Are the Growth Opportunities for RGEDF?
- Expansion into Emerging Markets: Gedeon Richter is focusing on expanding its presence in emerging markets, particularly in Asia and Africa, where the demand for pharmaceuticals is rapidly increasing. The global pharmaceutical market in these regions is expected to grow at a CAGR of 8% over the next five years, driven by rising healthcare access and investment. This expansion will allow Gedeon Richter to tap into new revenue streams and enhance its market share.
- Innovative Drug Development: The company is actively engaged in developing innovative therapies, particularly in the fields of gynecology and central nervous system disorders. With a strong pipeline of products in various stages of clinical trials, Gedeon Richter aims to introduce new medications that address unmet medical needs.
- Strategic Partnerships: Gedeon Richter is pursuing strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its R&D capabilities. These partnerships can accelerate the development of new drugs and facilitate entry into new markets. Collaborations in the pharmaceutical sector have shown to increase the success rate of drug development by up to 30%.
- Digital Health Initiatives: The company is investing in digital health technologies to improve patient engagement and medication adherence. By leveraging telemedicine and digital platforms, Gedeon Richter can enhance its service offerings and reach a broader patient base.
- Sustainability and Green Chemistry: Gedeon Richter is committed to sustainability and is incorporating green chemistry practices in its manufacturing processes. This focus not only reduces environmental impact but also aligns with global trends toward sustainable healthcare solutions. The market for sustainable pharmaceuticals is expected to grow significantly as consumers and regulators increasingly prioritize environmentally friendly practices.
What Are RGEDF's Competitive Advantages?
- Strong brand recognition in the pharmaceutical industry.
- Extensive R&D capabilities leading to innovative product offerings.
- Established distribution network ensuring wide market reach.
- Commitment to sustainability and green practices enhancing brand value.
- Long-standing history and expertise in pharmaceuticals since 1901.
What Does RGEDF Do?
Founded in 1901 by Gedeon Richter, Gedeon Richter PLC has established itself as a prominent player in the pharmaceutical industry. Headquartered in Budapest, Hungary, the company specializes in the development and manufacture of pharmaceuticals, operating through three main segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceuticals segment focuses on research and development, manufacturing, sales, and marketing of a diverse range of pharmaceutical products. The Wholesale & Retail segment encompasses the distribution of products through a network of companies and pharmacies, ensuring that consumers have access to the medications they need. The Other segment includes various marketing and sales support services provided by group members. Over the years, Gedeon Richter has expanded its geographic reach and product portfolio, positioning itself as a key player in the healthcare sector. With a workforce of over 10,943 employees, the company is dedicated to innovation and improving patient outcomes through its extensive research initiatives and strong market presence.
What Products and Services Does RGEDF Offer?
- Develop and manufacture a wide range of pharmaceutical products.
- Engage in research and development to innovate new therapies.
- Distribute products through a network of pharmacies and healthcare providers.
- Provide marketing and sales support services for pharmaceutical products.
- Focus on therapeutic areas such as gynecology and central nervous system disorders.
- Expand operations into emerging markets to capture new growth opportunities.
How Does RGEDF Make Money?
- Generate revenue through the sale of pharmaceutical products.
- Leverage a robust distribution network to reach consumers effectively.
- Invest in R&D to develop innovative therapies and maintain competitive advantage.
- Engage in strategic partnerships to enhance product offerings and market access.
- Provide marketing and sales support services to bolster product visibility.
What Industry Does RGEDF Operate In?
The pharmaceutical industry is experiencing robust growth, driven by increasing healthcare demands and advancements in drug development. Gedeon Richter PLC is well-positioned within this landscape, leveraging its strong R&D capabilities and extensive distribution network. Competition is intense, with major players focusing on innovation and market expansion. Gedeon Richter’s strategic initiatives in emerging markets and its commitment to developing novel therapies enhance its competitive edge.
Who Are RGEDF's Key Customers?
- Healthcare providers, including hospitals and clinics.
- Pharmacies and drugstores that distribute pharmaceutical products.
- Patients requiring medications for various health conditions.
- Government health agencies and institutions.
- Research institutions and academic partners for collaborative projects.
Company Profile
Gedeon Richter PLC operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Budapest, HU. The company is led by CEO Gábor Orbán. RGEDF has traded publicly since 2013.
Gedeon Richter PLC Financial Trajectory
Gedeon Richter PLC (RGEDF) reported $237.57B in revenue for Q2 2026, reflecting 8.1% growth compared to the prior quarter. The company recorded net income of $37.66B, with diluted EPS of $206.57. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, RGEDF averaged $293.83 in diluted EPS.
How Gedeon Richter PLC Is Valued
Gedeon Richter PLC carries a market capitalization of $7.65B, placing it in the mid-cap category. Relative to its peer group, RGEDF's quantitative score of 53/100 is below the peer average of 65/100.
Key Financial Metrics
Return on equity for Gedeon Richter PLC stands at 16.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.0%, showing how much profit it generates from its asset base. RGEDF trades at a trailing price-to-earnings ratio of 9.28, below the Healthcare sector average of ~23x. Its free cash flow yield is 11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Gedeon Richter PLC's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.10 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Gedeon Richter PLC revenue of about $940.41B for fiscal 2026, with EPS near $1516.25.
RGEDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong financial performance with high profit and gross margins.
- Established reputation and brand in the pharmaceutical market.
- Diverse product portfolio across multiple therapeutic areas.
- Robust R&D capabilities for innovative drug development.
Bear Case
- Dependency on specific therapeutic areas for revenue.
- Potential challenges in regulatory approvals for new drugs.
- Limited geographic presence compared to larger global competitors.
- Vulnerability to pricing pressures in the pharmaceutical industry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $237.57B | $37.66B | $206.57 |
| Q1 2026 | $219.81B | $65.17B | $357.22 |
| Q4 2025 | $247.27B | $68.60B | $376.52 |
| Q3 2025 | $212.45B | $42.90B | $235.00 |
Based on FMP financials and quantitative analysis
RGEDF Latest News
No recent news available for RGEDF.
RGEDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGEDF.
Price Targets
Wall Street price target analysis for RGEDF.
RGEDF MoonshotScore
What does this score mean?
The MoonshotScore rates RGEDF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gabor Orban
CEO
Gabor Orban has been leading Gedeon Richter PLC with a focus on innovation and growth. He has a strong background in pharmaceutical management and has held various leadership roles within the company. His educational credentials include a degree in pharmacy and an MBA, equipping him with the necessary skills to navigate the complexities of the pharmaceutical industry.
Track Record: Under Gabor Orban's leadership, Gedeon Richter has expanded its product pipeline significantly and entered new international markets. His strategic vision has driven the company's growth and enhanced its competitive positioning in the pharmaceutical sector.
RGEDF OTC Market Information
The OTC Other tier includes companies that do not meet the stringent listing requirements of major exchanges like NYSE or NASDAQ. This tier allows smaller companies to trade publicly, providing liquidity and access to capital markets, albeit with potentially lower visibility and higher risks.
- OTC Tier: OTC Other
- Lower visibility and investor awareness compared to exchange-listed peers.
- Potential for higher volatility in stock price due to lower trading volumes.
- Limited access to capital markets for raising funds.
- Regulatory scrutiny may differ from that of larger exchanges.
- Review the company's financial statements and disclosures.
- Assess the management team's experience and track record.
- Evaluate the competitive landscape and market position.
- Investigate any pending regulatory approvals or challenges.
- Consider the company's growth strategy and market expansion plans.
- Established history since 1901, indicating stability and experience.
- Strong financial performance metrics, including profit and gross margins.
- Active engagement in R&D and innovation within the pharmaceutical sector.
Common Questions About RGEDF (Healthcare)
What does the AI Score mean for RGEDF?
RGEDF holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Gedeon Richter PLC is a Hungarian pharmaceutical company specializing in the development and manufacture of pharmaceuticals. Founded in 1901, it operates in multiple segments, including …
What does Gedeon Richter PLC do?
Gedeon Richter PLC specializes in the development and manufacture of pharmaceuticals, focusing on research and development, sales, and marketing of various therapeutic products. The company operates through three segments: Pharmaceuticals, Wholesale & Retail, and Others, ensuring a comprehensive approach to healthcare solutions.
What is Gedeon Richter PLC's drug pipeline status?
Gedeon Richter PLC has a robust drug pipeline with several products in various stages of clinical trials, particularly in gynecology and central nervous system disorders. The company is actively pursuing innovative therapies to address unmet medical needs, which could significantly impact its future revenue and market positioning.
What are the main risks for RGEDF?
Gedeon Richter PLC faces several risks, including regulatory challenges that could delay drug approvals, intense competition from larger pharmaceutical companies, and market volatility that may affect pricing and profitability. Additionally, the company must navigate the risks associated with patent expirations and the increasing presence of generic alternatives.
What are the key factors to evaluate for RGEDF?
Gedeon Richter PLC (RGEDF) holds an AI score of 53/100 (moderate). P/E: 9.3x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does RGEDF data refresh on this page?
RGEDF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGEDF's recent stock price performance?
Gedeon Richter PLC (RGEDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong financial performance with high profit and gross margins. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGEDF overvalued or undervalued right now?
Gedeon Richter PLC (RGEDF) trades at 9.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGEDF before investing?
Before investing in Gedeon Richter PLC (RGEDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is subject to periodic updates and may vary based on market conditions.